How to Evaluate KarXT Symptom Domains in Schizophrenia
How can clinicians assess whether KarXT is improving symptom domains beyond positive symptoms in acute schizophrenia?
In schizophrenia, treatment response is often judged mainly by positive symptom change, which can miss broader effects on thought disorder, hostility, or affective symptoms. This analysis used the PANSS Marder 5-factor model to show how KarXT response can be assessed across multiple symptom domains during acute inpatient treatment.
-
Assess symptoms with a PANSS 5-factor framework
Go beyond the original PANSS positive and negative subscales by organizing symptom review around the Marder 5-factor model used in the article. The five domains are positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility, and anxiety/depression.
-
Measure domain change from baseline through week 5
Use baseline assessment and serial follow-up visits to track whether each factor is improving over time. In the study, PANSS assessments occurred at baseline and at weeks 2, 4, and 5, allowing early and endpoint evaluation of domain-level change.
-
Look for broad multidomain improvement by week 2
Between-group differences favoring KarXT were significant starting at week 2 for all five Marder factors. Based on this study, the first postbaseline assessment is the earliest point at which clinicians could reasonably expect broad symptom-domain separation from placebo.
-
Use week 5 to confirm breadth of response
By week 5, KarXT showed significant improvement over placebo in all five PANSS Marder factors. Reported effect sizes ranged from 0.48 to 0.66, supporting clinically relevant benefit across positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility, and anxiety/depression.
-
Interpret negative symptom change cautiously in acute psychosis
The authors note that PANSS factors may not be fully independent in acute schizophrenia and that some items, especially negative symptom items, may improve secondarily as positive symptoms improve. The 5-factor analysis therefore does not establish improvement in enduring primary negative symptoms.
Clinical Considerations
- The five PANSS factors may not be independent of one another in acute schizophrenia.
- Observed improvement in negative symptom items may reflect secondary improvement linked to reduced positive symptoms rather than durable change in primary negative symptoms.
- These findings are preliminary because they come from a single phase 2 study.
- The short 5-week study cannot determine the longer-term persistence of domain-level improvement.
Bottom Line
When evaluating KarXT in acute schizophrenia, assess response across all five PANSS Marder domains by week 2 and week 5 rather than focusing only on positive symptoms.
